SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Non-TechAttractive opportunities in already announced mergers


Previous 10 Next 10 
To: D. K. G. who wrote (44)11/17/2011 8:42:40 AM
From: D. K. G.
   of 64
 
Keeping an eye on SNDA. Spread might widen in weak market.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: D. K. G. who wrote (45)12/15/2011 10:23:55 AM
From: D. K. G.
   of 64
 
Merger Arbitrage Dynamics: Pharmasset (VRUS)
  • Posted by kid dynamite
  • on December 7th, 2011


  • kiddynamitesworld.com

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: D. K. G. who wrote (46)1/6/2012 3:48:16 PM
    From: D. K. G.
       of 64
     
    VRUS spread has been tightening since last week. An indication the market thinks the risk is off and the deal will be finalized. Just got notice to tender shares by COB Jan 10th. I took advantage last week, there's still some chicken left of this bone.

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: D. K. G. who wrote (47)1/13/2012 8:05:38 AM
    From: D. K. G.
       of 64
     
    .....Gilead nears completion of Pharmasset deal

    Gilead Sciences now owns 95 percent of Pharmasset in $11 billion acquisition



    Associated Press – Thu, Jan 12, 2012 7:21 AM EST

    ....

    Share0EmailPrint.....Companies:...Pharmasset, Inc.Gilead Sciences Inc. . ..RELATED QUOTES.

    .Symbol Price Change

    VRUS 136.92 0.00



    GILD 44.90 0.00



    ......



    FOSTER CITY, Calif. (AP) -- Gilead Sciences has acquired about 95 percent of the outstanding shares in Pharmasset as it draws closer to closing its $11 billion deal for the drug developer.



    Gilead, based in Foster City, Calif., said about 72 million Pharmasset shares have been tendered. Gilead announced in November that it would pay $137 per share in cash for the, a Princeton, N.J. drug developer.



    Pharmasset Inc. has three potential hepatitis C treatments in clinical testing, including a candidate labeled PSI-7977 in late-stage testing. Analysts see promise in the drug because doctors may be able prescribe the pill in a combination with other treatments that does not involve interferon, an injection that comes with rough side effects.



    Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States. Analysts expect it to become a bigger health problem as baby boomers ages.



    Gilead Sciences Inc. plans to buy additional shares of Pharmasset directly from the company, which has no drugs on the market. The acquisition is expected to close in the first quarter.



    .

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: D. K. G. who wrote (48)1/13/2012 1:47:46 PM
    From: D. K. G.
       of 64
     
    merger-arbs-cleaning-up-in-inhibitex-buyout

    247wallst.com

    Share RecommendKeepReplyMark as Last Read


    From: Paul Senior3/13/2012 9:50:42 PM
       of 64
     
    VQ: I'm upping my VQ shares, betting that the cash offer for the company at $12.50 gets done. And within next 90-180 days.

    finance.yahoo.com

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: Paul Senior who wrote (50)5/22/2012 10:47:08 AM
    From: D. K. G.
       of 64
     
    Started a VQ position from SNDA and MMI proceeds.

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: D. K. G. who wrote (51)5/22/2012 12:28:01 PM
    From: Paul Senior
       of 64
     
    VQ is so low compared to buyout price that I'm a little worried that the deal won't get done. However, I am holding on to my position and sticking with my bet that it'll get completed.

    The deal I'm most enthused now about is Viterra (VTRAF/VT.to), and I have a substantially larger bet on that one. With Viterra, while the gain (%) isn't so large as VQ might or will be, the acquiring company really wants Viterra and has the financing to do the deal (I believe). The two issues seem to be: 1) will the local Canadian government block the deal, and/or 2) will the deal be delayed to such an extent that given the time value of money, it's not worth holding Viterra until the deal actually gets completed.

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: Paul Senior who wrote (52)5/22/2012 1:16:03 PM
    From: D. K. G.
       of 64
     
    Re VQ yep, that's the risk in arb. Looks to be finding a bottom so I'm fishing today. I'll set a stop loss to limit downside 7% or so for a potential higher return should the deal go through.

    Looks like June12th for VQ?

    GL with Viterra.

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)


    To: D. K. G. who wrote (53)5/23/2012 10:42:16 AM
    From: D. K. G.
       of 64
     
    VQ tape is weak...not a bottom yet..fish around 9..some support there.

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)
    Previous 10 Next 10